LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Stryker Corp

Stryker Corp

Gesloten

SectorGezondheidszorg

316.09 0.8

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

315.23

Max

317.64

Belangrijke statistieken
By Trading Economics
Inkomsten	-104M 745M
Verkoop	-1.2B 6B
K/W Sectorgemiddelde	36.252 49.701
EPS	1.93
Dividendrendement	1.12
Winstmarge	12.375
Werknemers	56,000
EBITDA	-478M 1.2B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+23.76% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.12% 2.39%
Volgende Winsten	30 jul 2026
Volgende dividenddatum	30 jul 2026
Volgende Ex Dividend datum	29 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5.9B 120B
Vorige openingsprijs	315.29
Vorige sluitingsprijs	316.09

Nieuwssentiment

By Acuity

54%

46%

279 / 345 Rangschikking in Healthcare

Stryker Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 apr 2026, 20:41 UTC

Winsten

Stryker 1Q Sales, Profit Rise as it Dealt with Cyberattack

12 mrt 2026, 21:42 UTC

Belangrijke Nieuwsgebeurtenissen

Stryker Says Cyberattack Disruption Is Continuing

11 mrt 2026, 19:18 UTC

Belangrijke Marktbewegers

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

29 jan 2026, 22:05 UTC

Winsten

Stryker Logs Higher 4Q Profit On Sales Gains

30 okt 2025, 20:36 UTC

Winsten

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

30 apr 2026, 20:06 UTC

Winsten

Stryker 1Q Organic Net Sales Up 2.4%

30 apr 2026, 20:06 UTC

Winsten

Stryker Backs FY26 Adj EPS $14.90-Adj EPS $15.10 >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker Still Sees FY26 Organic Sales Grwoth 8% to 9.5%

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q Adj EPS $2.60 >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q EPS $1.93 >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q Net $745M >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q Sales $6.02B >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q Net $745M >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q Adj EPS $2.60 >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q EPS $1.93 >SYK

30 apr 2026, 20:05 UTC

Winsten

Stryker 1Q Sales $6B >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

16 mrt 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

30 jan 2026, 17:03 UTC

Marktinformatie

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

29 jan 2026, 21:07 UTC

Winsten

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

29 jan 2026, 21:05 UTC

Winsten

Stryker 4Q Adj EPS $4.47 >SYK

5 nov 2025, 19:38 UTC

Winsten

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5 nov 2025, 17:00 UTC

Winsten

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

30 okt 2025, 20:21 UTC

Winsten

Stryker Lifts FY Sales View After 3Q Revenue Rises

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.1B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

Peer Vergelijking

Prijswijziging

Stryker Corp Prognose

Koersdoel

By TipRanks

23.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 391.67 USD 23.76%

Hoogste 465 USD

Laagste 315 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Stryker Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

23 ratings

Buy

Hold

Sell

Gebaseerd op 23 analisten die aandelenratings hebben gegeven aan Stryker Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

279 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.